Evidence map›Paper›PMID 31300848›Full record

ReviewRheumatology international2019

Comorbidity burden in systemic sclerosis: beyond disease-specific complications.

Eleni Pagkopoulou, Alexandra Arvanitaki, Dimitrios Daoussis, Alexandros Garyfallos, George Kitas, Theodoros Dimitroulas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Respiratory failure in systemic sclerosis.Rheumatology international · 2024
    Review
  4. Observational
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Eleni PagkopoulouFourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Str, 54642, Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-5755-1538
Alexandra ArvanitakiCardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0003-3180-7280
Dimitrios DaoussisDepartment of Rheumatology, Faculty of Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece.ORCID http://orcid.org/0000-0001-8027-3655
Alexandros GaryfallosFourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Str, 54642, Thessaloniki, Greece.ORCID http://orcid.org/0000-0001-7289-1293
George KitasDepartment of Rheumatology, Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, West Midlands, UK.ORCID http://orcid.org/0000-0002-0828-6176
Theodoros DimitroulasFourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Str, 54642, Thessaloniki, Greece. dimitroul@hotmail.com.ORCID http://orcid.org/0000-0002-0364-1642
Aristotle University of Thessaloniki · GRRussells Hall Hospital · GBUniversity of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) is a chronic, systemic disease characterized by fibrosis of the skin and internal organs, vasculopathy, and auto-immune activation. On the top of severe organ involvement such as interstitial lung and myocardial fibrosis, pulmonary hypertension, and renal crisis, individuals diagnosed with SSc may suffer from a number of comorbidities. This is a narrative review according to published recommendations and we searched the online databases MEDLINE and EMBASE using as key words the following terms: systemic sclerosis, scleroderma, myocardial fibrosis in combination with micro- and macro-vascular disease, cardiac involvement, atherosclerosis, cardiovascular disease and coronary arteries, infections, cancer, depression, osteoporosis, and dyslipidemia. Although data are usually inconclusive it appears that comorbidities with significant impact on life expectancy, namely cardiovascular disease, infections, and cancer as well as phycological disorders affecting emotional and mental health are highly prevalent in SSc population. Thereafter, the aim of this review is to summarize the occurrence and the clinical significance of such comorbidities in SSc population and to discuss how rheumatologists can incorporate the management of these conditions in daily clinical practice.

Indexed as

AtherosclerosisCommunicable DiseasesComorbidityCoronary Artery DiseaseCost of IllnessDyslipidemiasEmotionsHumansLife ExpectancyMental HealthNeoplasmsOsteoporosisQuality of LifeRisk FactorsScleroderma, SystemicCancerComorbiditiesDepressionInfectionsSclerodermaSystemic Sclerosis

Identifiers

PMID31300848
OpenAlexW2961627580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.